Syringaresinol causes vasorelaxation by elevating nitric oxide production through the phosphorylation and dimerization of endothelial nitric oxide synthase.
10.3858/emm.2012.44.3.014
- Author:
Byung Hee CHUNG
1
;
Sookon KIM
;
Jong Dai KIM
;
Jung Joon LEE
;
Yi Yong BAEK
;
Dooil JEOUNG
;
Hansoo LEE
;
Jongseon CHOE
;
Kwon Soo HA
;
Moo Ho WON
;
Young Guen KWON
;
Young Myeong KIM
Author Information
1. Vascular System Research Center, School of Medicine, Kangwon National University, Chuncheon 200-701, Korea. ymkim@kangwon.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
nitric oxide synthase type III;
phosphorylation;
protein multimerization;
syringaresinol;
type C phospholipases;
vasodilation
- MeSH:
Animals;
Aorta/*drug effects/physiology;
Enzyme Activation/drug effects;
Furans/*pharmacology;
Gene Deletion;
Human Umbilical Vein Endothelial Cells/drug effects/metabolism;
Humans;
Lignans/*pharmacology;
Mice;
Mice, Inbred C57BL;
Nitric Oxide/metabolism;
Nitric Oxide Synthase Type III/genetics/*metabolism;
Phosphatidylinositol 3-Kinases/metabolism;
Phosphoinositide Phospholipase C/metabolism;
Phosphorylation/drug effects;
Protein Multimerization/*drug effects;
Proto-Oncogene Proteins c-akt/metabolism;
Vasodilation/*drug effects
- From:Experimental & Molecular Medicine
2012;44(3):191-201
- CountryRepublic of Korea
- Language:English
-
Abstract:
Nitric oxide (NO) produced by endothelial NO synthase (eNOS) plays an important role in vascular functions, including vasorelaxation. We here investigated the pharmacological effect of the natural product syringaresinol on vascular relaxation and eNOS-mediated NO production as well as its underlying biochemical mechanism in endothelial cells. Treatment of aortic rings from wild type, but not eNOS-/- mice, with syringaresinol induced endothelium-dependent relaxation, which was abolished by addition of the NOS inhibitor NG-monomethyl-L-arginine. Treatment of human endothelial cells and mouse aortic rings with syringaresinol increased NO production, which was correlated with eNOS phosphorylation via the activation of Akt and AMP kinase (AMPK) as well as elevation of intracellular Ca2+ levels. A phospholipase C (PLC) inhibitor blocked the increases in intracellular Ca2+ levels, AMPK-dependent eNOS phosphorylation, and NO production, but not Akt activation, in syringaresinol-treated endothelial cells. Syringaresinol-induced AMPK activation was inhibited by co-treatment with PLC inhibitor, Ca2+ chelator, calmodulin antagonist, and CaMKKbeta siRNA. This compound also increased eNOS dimerization, which was inhibited by a PLC inhibitor and a Ca2+-chelator. The chemicals that inhibit eNOS phosphorylation and dimerization attenuated vasorelaxation and cGMP production. These results suggest that syringaresinol induces vasorelaxation by enhancing NO production in endothelial cells via two distinct mechanisms, phosphatidylinositol 3-kinase/Akt- and PLC/Ca2+/CaMKKbeta-dependent eNOS phosphorylation and Ca2+-dependent eNOS dimerization.
